#

19-21 SEPTEMBER 2017 //

MARITIM PROARTE HOTEL, BERLIN

Latest Videos

Interview with Dr Martin Andrews, GSK’s SVP of Rare Diseases

Strimvelis is the first ex-vivo stem cell gene therapy to treat patients with Severe Combined Immunodeficiency due to Adenosine Deaminase deficiency, or commonly known as 'Bubble Boy Disease'). We caught up with Dr Andrews, who leads GSK's Rare Disease Development team at our Miami Leaders Forum 2017.

Video on genome editing

Watch the following video where Edward Lanphier -President & Chief Executive Officer, Sangamo BioSciences Inc/Chairman, Alliance for Regenerative Medicine (ARM)- talks about 'Overcoming the challenges of conventional gene therapy':

PHACILITATE LEADERS EUROPE 2016

Watch what happened on the first day at Phacilitate Leaders Europe 2016:

Discussing the future of the supply chain with Invetech, TrakCel and Brooks:

 

Interview with Dr Sven Kili

One of the big gene therapy success stories of 2016 so far has been the approval of GlaxoSmithKline’s Strimvelis by the European Commission, to treat patients with ADA-SCID.

Ahead of Phacilitate’s Cell & Gene Therapy Europe next week, we had the pleasure of talking with Dr Sven Kili, VP and Head of Cell & Gene Therapy Development at GlaxoSmithKline about the next steps now that Strimvelis has been approved, the changing model of orphan drug designation, and how the commercial supply chain strategy for Strimvelis is taking shape.

Watch the full interview online here:

Future of bioprocessing

Hear experts discussing the future of bioprocessing from CRC for Cell Therapy Manufacturing, Saint-Gobain and Akron Biotechnology.

HIGHLIGHTS of Cell & Gene Therapy Europe

Watch the what happended last September at Cell & Gene Therapy Europe 2015!

Investment Insights

At last year' s Cell & Gene Therapy Europe event we talked with leading VCs from the sector and asked them some of the burning questions around funding. View the video below to see what they had to say:

HTA and industry perspectives

Watch the whole presentation on 'Profiling the current environment and predicting the future for ATMP evaluation, pricing and reimbursement in Europe' that was recorded at Cell & Gene Therapy Europe 2015.

Advisory Board

"It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance."

Bertrand Alexandre, Director, Marketing Europe, Celyad

Sponsors

  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #